Not all cancers have identifiable targets, and not all patients will benefit from targeted agents. These therapies are most effective in cancers where the specific molecular targets are well understood. Genetic testing and biomarker analysis are often used to determine if a patient’s cancer has the specific characteristics that make it amenable to targeted therapy. For example, patients with HER2-positive breast cancer can benefit from HER2-targeted therapies.
